{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:16:59Z","timestamp":1772122619930,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,26]]},"DOI":"10.7759\/cureus.104294","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:41:48Z","timestamp":1772120508000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological Profile and Real-World Survival Outcomes in Pure Uterine Sarcomas"],"prefix":"10.7759","author":[{"given":"Ritu","family":"Ahlawat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Vuppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranidhashree","family":"C. A","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anusree","family":"K","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Bhati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India","volume":"156","author":"Sathishkumar K","year":"2022","unstructured":"Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian J Med Res. 2022, 156:598-607. 10.4103\/ijmr.ijmr_1821_22","journal-title":"Indian J Med Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-018-0860-5","article-title":"Uterine sarcomas: experience from a tertiary cancer care center from India","volume":"10","author":"Nusrath S","year":"2019","unstructured":"Nusrath S, Bafna S, Rajagopalan R, et al.. Uterine sarcomas: experience from a tertiary cancer care center from India. Indian J Surg Oncol. 2019, 10:342-9. 10.1007\/s13193-018-0860-5","journal-title":"Indian J Surg Oncol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1136\/jcp.55.5.321","article-title":"Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?","volume":"55","author":"McCluggage WG","year":"2002","unstructured":"McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?. J Clin Pathol. 2002, 55:321-5.","journal-title":"J Clin Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1055\/a-1545-4279","article-title":"2020 WHO classification of female genital tumors","volume":"81","author":"H\u00f6hn AK","year":"2021","unstructured":"H\u00f6hn AK, Brambs CE, Hiller GG, May D, Schmoeckel E, Horn LC. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd. 2021, 81:1145-53. 10.1055\/a-1545-4279","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2020.2151","article-title":"Diagnosis, treatment and survival of uterine sarcoma: a retrospective cohort study of 122 cases","volume":"13","author":"Plentz TB","year":"2020","unstructured":"Plentz TB, Candido EC, Dias LF, Toledo MC, Vale DB, Teixeira JC. Diagnosis, treatment and survival of uterine sarcoma: a retrospective cohort study of 122 cases. Mol Clin Oncol. 2020, 13:81. 10.3892\/mco.2020.2151","journal-title":"Mol Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231157645","article-title":"Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)","volume":"15","author":"P\u00e9rez-Fidalgo JA","year":"2023","unstructured":"P\u00e9rez-Fidalgo JA, Ortega E, Ponce J, et al.. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Ther Adv Med Oncol. 2023, 15:17588359231157645. 10.1177\/17588359231157645","journal-title":"Ther Adv Med Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134644","article-title":"Challenges in differentiating uterine mesenchymal tumors-key diagnostic criteria","volume":"14","author":"Dani\u0142owska K","year":"2025","unstructured":"Dani\u0142owska K, Satora M, Ku\u0142ak K, Ku\u0142ak A, Tarkowski R. Challenges in differentiating uterine mesenchymal tumors-key diagnostic criteria. J Clin Med. 2025, 14:4644. 10.3390\/jcm14134644","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4274\/jtgga.galenos.2022.2021.9-17","article-title":"Effect of tumor morcellation in patients with early uterine sarcoma: a multicenter study in Germany","volume":"23","author":"Gitas G","year":"2022","unstructured":"Gitas G, Ertan K, Baum S, et al.. Effect of tumor morcellation in patients with early uterine sarcoma: a multicenter study in Germany. J Turk Ger Gynecol Assoc. 2022, 23:75-82. 10.4274\/jtgga.galenos.2022.2021.9-17","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.39773","article-title":"A real-world study on diagnosis and treatment of uterine sarcoma in Western China","volume":"16","author":"Li D","year":"2020","unstructured":"Li D, Yin N, Du G, Wang S, Xiao Z, Chen J, Chen W. A real-world study on diagnosis and treatment of uterine sarcoma in Western China. Int J Biol Sci. 2020, 16:388-95. 10.7150\/ijbs.39773","journal-title":"Int J Biol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.30699\/jogcr.10.3.189","article-title":"Retrospective analysis of uterine sarcoma cases managed by a single institute","volume":"10","author":"Yahaya AS","year":"2025","unstructured":"Yahaya AS, Mohd Abas MN, Omar J. Retrospective analysis of uterine sarcoma cases managed by a single institute. J Obstet Gynecol Cancer Res. 2025, 10:189-200. 10.30699\/jogcr.10.3.189","journal-title":"J Obstet Gynecol Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S117754","article-title":"Uterine sarcoma - current perspectives","volume":"9","author":"Benson C","year":"2017","unstructured":"Benson C, Miah AB. Uterine sarcoma - current perspectives. Int J Womens Health. 2017, 9:597-606. 10.2147\/IJWH.S117754","journal-title":"Int J Womens Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4680273","article-title":"Treatment of recurrent or metastatic uterine adenosarcoma","volume":"2017","author":"Nathenson MJ","year":"2017","unstructured":"Nathenson MJ, Conley AP, Lin H, Fleming N, Ravi V. Treatment of recurrent or metastatic uterine adenosarcoma. Sarcoma. 2017, 2017:4680273. 10.1155\/2017\/4680273","journal-title":"Sarcoma"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2023.06.016","article-title":"Uterine sarcomas: a critical review of the literature","volume":"287","author":"Giannini A","year":"2023","unstructured":"Giannini A, Golia D'Aug\u00e8 T, Bogani G, et al.. Uterine sarcomas: a critical review of the literature. Eur J Obstet Gynecol Reprod Biol. 2023, 287:166-70. 10.1016\/j.ejogrb.2023.06.016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004204","article-title":"Prognostic factors in patients with uterine sarcoma: the SARCUT study","volume":"33","author":"Zapardiel I","year":"2023","unstructured":"Zapardiel I, Gracia Segovia M, Macuks R, et al.. Prognostic factors in patients with uterine sarcoma: the SARCUT study. Int J Gynecol Cancer. 2023, 33:897-904. 10.1136\/ijgc-2022-004204","journal-title":"Int J Gynecol Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D'Angelo E","year":"2010","unstructured":"D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010, 116:131-9. 10.1016\/j.ygyno.2009.09.023","journal-title":"Gynecol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101992","article-title":"Uterine leiomyosarcoma","volume":"35","author":"Bogani G","year":"2025","unstructured":"Bogani G, Caruso G, Ray-Coquard I, et al.. Uterine leiomyosarcoma. Int J Gynecol Cancer. 2025, 35:101992. 10.1016\/j.ijgc.2025.101992","journal-title":"Int J Gynecol Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.11.002","article-title":"Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: a retrospective MITO group study","volume":"144","author":"Raspagliesi F","year":"2017","unstructured":"Raspagliesi F, Maltese G, Bogani G, et al.. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: a retrospective MITO group study. Gynecol Oncol. 2017, 144:90-5. 10.1016\/j.ygyno.2016.11.002","journal-title":"Gynecol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004292","article-title":"Uterine morcellation for presumed leiomyomas: ACOG Committee Opinion Summary, Number 822","volume":"137","year":"2021","unstructured":"Uterine morcellation for presumed leiomyomas. ACOG Committee Opinion Summary, Number 822. Obstet Gynecol. 2021, 137:552-3. 10.1097\/AOG.0000000000004292","journal-title":"Obstet Gynecol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas","volume":"34","author":"Ray-Coquard I","year":"2024","unstructured":"Ray-Coquard I, Casali PG, Croce S, et al.. ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas. Int J Gynecol Cancer. 2024, 34:1499-521. 10.1136\/ijgc-2024-005823","journal-title":"Int J Gynecol Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00454","article-title":"Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology\/Gynecologic Oncology Group Study","volume":"36","author":"Hensley ML","year":"2018","unstructured":"Hensley ML, Enserro D, Hatcher H, et al.. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology\/Gynecologic Oncology Group Study. J Clin Oncol. 2018, 36:JCO1800454. 10.1200\/JCO.18.00454","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds545","article-title":"A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group","volume":"24","author":"Pautier P","year":"2013","unstructured":"Pautier P, Floquet A, Gladieff L, et al.. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol. 2013, 24:1099-104. 10.1093\/annonc\/mds545","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)","volume":"44","author":"Reed NS","year":"2008","unstructured":"Reed NS, Mangioni C, Malmstr\u00f6m H, et al.. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008, 44:808-18. 10.1016\/j.ejca.2008.01.019","journal-title":"Eur J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.077","article-title":"The role of adjuvant radiation in uterine sarcomas","volume":"76","author":"Sampath S","year":"2010","unstructured":"Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2010, 76:728-34. 10.1016\/j.ijrobp.2009.02.077","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx258","article-title":"Corrigendum","volume":"28","year":"2017","unstructured":"Corrigendum. Ann Oncol. 2017, 28.iv167-8. 10.1093\/annonc\/mdx258","journal-title":"Ann Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11000-3","article-title":"Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years' clinical experience from a tertiary care center in Pakistan","volume":"23","author":"Khan SR","year":"2023","unstructured":"Khan SR, Soomar SM, Asghari T, Ahmed A, Moosajee MS. Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years' clinical experience from a tertiary care center in Pakistan. BMC Cancer. 2023, 23:510. 10.1186\/s12885-023-11000-3","journal-title":"BMC Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03415-3","article-title":"Clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma","volume":"19","author":"Yuan H","year":"2024","unstructured":"Yuan H, Wang Y, Li N, Wu L, Yao H. Clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma. Orphanet J Rare Dis. 2024, 19:395. 10.1186\/s13023-024-03415-3","journal-title":"Orphanet J Rare Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_350541","article-title":"Novel therapeutics in the treatment of uterine sarcoma","volume":"42","author":"Bose S","year":"2022","unstructured":"Bose S, Schwartz GK, Ingham M. Novel therapeutics in the treatment of uterine sarcoma. Am Soc Clin Oncol Educ Book. 2022, 42:900-9. 10.1200\/EDBK_350541","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473106","article-title":"Rare uterine tumors: what to do?","volume":"45","author":"Crane E","year":"2025","unstructured":"Crane E, Gaillard S, Hensley ML. Rare uterine tumors: what to do?. Am Soc Clin Oncol Educ Book. 2025, 45:e473106. 10.1200\/EDBK-25-473106","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/451886-clinicopathological-profile-and-real-world-survival-outcomes-in-pure-uterine-sarcomas","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:41:49Z","timestamp":1772120509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/451886-clinicopathological-profile-and-real-world-survival-outcomes-in-pure-uterine-sarcomas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.104294","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}